| 
																	
																		 
																		 Phenylpropionates
 
																		 
																		
																	 
																		 
																		
																	 
																			
																					
	"Phenylpropionates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
 
	
	
		
			
			
				Derivatives of 3-phenylpropionic acid, including its salts and esters.
    
			 
				
				
					
						| Descriptor ID | D010666 |  
						| MeSH Number(s) | D02.241.223.701 |  
						| Concept/Terms |  |  
				Below are MeSH descriptors whose meaning is more general than "Phenylpropionates". 
				Below are MeSH descriptors whose meaning is more specific than "Phenylpropionates". 
	
	
		
			
			
					
				This graph shows the total number of publications written about "Phenylpropionates" by people in this website by year, and whether "Phenylpropionates" was a major or minor topic of these publications.  
					  To see the data from this visualization as text, click here. 
		            | Year | Major Topic | Minor Topic | Total | 
|---|
 | 2005 | 1 | 0 | 1 |  | 2008 | 2 | 0 | 2 |  | 2009 | 1 | 0 | 1 |  | 2011 | 1 | 1 | 2 |  | 2012 | 1 | 0 | 1 |  | 2017 | 2 | 0 | 2 |  | 2019 | 0 | 2 | 2 |  | 2022 | 1 | 0 | 1 |  | 2025 | 1 | 0 | 1 | 
 
                    To return to the timeline, click here. 
				Below are the most recent publications written about "Phenylpropionates" by people in Profiles. 		
					
								
								Durieu I, Clements B, Fabrizzi B, Mall MA, McKone E, Ramsey B, Tullis E, Taylor-Cousar JL, van der Meer R, Bachman E, Chin A, Conner S, Jennings M, Weinstock T, Colombo C, Robinson P. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. Am J Respir Crit Care Med. 2025 Oct; 211(10):1926-1934.
								Issapour A, Frank B, Crook S, Hite MD, Dorn ML, Rosenzweig EB, Ivy DD, Krishnan US. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience. Pediatr Pulmonol. 2022 03; 57(3):724-733.
								Chen JR, Zhao H, Wankhade UD, Chintapalli SV, Li C, Gai D, Shankar K, Zhan F, Lazarenko OP. GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice. Commun Biol. 2021 01 08; 4(1):53.
								Preston IR, Burger CD, Bartolome S, Safdar Z, Krowka M, Sood N, Ford HJ, Battarjee WF, Chakinala MM, Gomberg-Maitland M, Hill NS. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial. J Heart Lung Transplant. 2020 05; 39(5):464-472.
								Ferguson SK, Pak DI, Hopkins JL, Harral JW, Redinius KM, Loomis Z, Stenmark KR, Borden MA, Schroeder T, Irwin DC. Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases. Drug Deliv. 2019 Dec; 26(1):147-157.
								Anderson EM, Stone ML, Katahira R, Reed M, Muchero W, Ramirez KJ, Beckham GT, Rom?n-Leshkov Y. Differences in S/G ratio in natural poplar variants do not predict catalytic depolymerization monomer yields. Nat Commun. 2019 05 02; 10(1):2033.
								Schroeder T, Piantadosi CA, Natoli MJ, Autmizguine J, Cohen-Wolkowieczs M, Hamilton KL, Bell C, Klawitter J, Christians U, Irwin DC, Noveck RJ. Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia. Clin Pharmacol Ther. 2018 05; 103(5):888-898.
								Kasztan M, Fox BM, Speed JS, De Miguel C, Gohar EY, Townes TM, Kutlar A, Pollock JS, Pollock DM. Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice. J Am Soc Nephrol. 2017 Aug; 28(8):2443-2458.
								Fischer A, Denton CP, Matucci-Cerinic M, Gillies H, Blair C, Tislow J, Nathan SD. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. Respir Med. 2016 08; 117:254-63.
								Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Wells AU, Shao L, Zhou H, Henig N, Szwarcberg J, Gillies H, Montgomery AB, O'Riordan TG. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J. 2015 Nov; 46(5):1370-7. | 
																	
																		
																			
																					People  People who have written about this concept._ 
    
        Similar Concepts   
        People who have written about this concept.
     _ 
    
        Top Journals   
        Top journals in which articles about this concept have been published.
     |